Drug Profile
Fluticasone propionate intranasal - OptiNose
Alternative Names: FLU-EDS; OPN-375; Opt-FP; OPTINOSE; OptiNose fluticasone propionate; XHANCELatest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator OptiNose AS
- Developer OptiNose
- Class Analgesics; Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Inorganic sulfur compounds; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Nasal polyps
- Registered Rhinosinusitis
- No development reported Asthma
Most Recent Events
- 15 Mar 2024 Registered for Rhinosinusitis in USA (Intranasal)
- 06 Dec 2023 US FDA assigns PDUFA action date of 16/03/2024 for XHANCE® fluticasone propionate for Chronic rhinosinusitis
- 06 Dec 2023 US FDA extends the review period of the sNDA for Fluticasone propionate as a treatment for Rhinosinusitis